Literature DB >> 22929872

Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice.

Christoph U Correll1, Juan A Gallego.   

Abstract

Antipsychotic polypharmacy (APP) is common in the treatment of schizophrenia spectrum disorders. The literature indicates that APP is related to patient, illness, and treatment variables that are proxy measures for greater illness acuity, severity, complexity, and chronicity. The largely unknown relative risks and benefits of APP need to be weighed against the known risks and benefits of clozapine for treatment-resistant patients. To inform evidence-based clinical practice, controlled, high-quality antipsychotic combination and discontinuation trials are necessary to determine the effectiveness, safety, and role of APP in the management of severely ill patients with insufficient response to antipsychotic monotherapy.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22929872      PMCID： PMC3717367          DOI： 10.1016/j.psc.2012.06.007

Source DB:  PubMed          Journal:  Psychiatr Clin North Am        ISSN： 0193-953X


  133 in total

1.  Subject selection biases in clinical trials: data from a multicenter schizophrenia treatment study.

Authors:  D Robinson; M G Woerner; S Pollack; G Lerner
Journal:  J Clin Psychopharmacol       Date:  1996-04       Impact factor: 3.153

2.  [The use of psychotropic drugs in an Italian psychiatric hospital: a two-year-long follow-up study].

Authors:  P Brambilla; E Monzani; M Alessandri; M Frova; C Barbui; A Erlicher
Journal:  Epidemiol Psichiatr Soc       Date:  1999 Oct-Dec

Review 3.  World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, Part 1: acute treatment of schizophrenia.

Authors:  Peter Falkai; Thomas Wobrock; Jeffrey Lieberman; Birte Glenthoj; Wagner F Gattaz; Hans-Jürgen Möller
Journal:  World J Biol Psychiatry       Date:  2005       Impact factor: 4.132

4.  Antipsychotic utilisation and polypharmacy in Italian residential facilities: a survey.

Authors:  L Ghio; W Natta; S Gotelli; L Ferrannini
Journal:  Epidemiol Psychiatr Sci       Date:  2011-06       Impact factor: 6.892

5.  Multiple antipsychotic medication prescribing patterns.

Authors:  Jennifer E Schumacher; Eugene H Makela; Holly R Griffin
Journal:  Ann Pharmacother       Date:  2003 Jul-Aug       Impact factor: 3.154

6.  A survey of prescribing of psychotropic drugs in a Birmingham psychiatric hospital.

Authors:  S Edwards; V Kumar
Journal:  Br J Psychiatry       Date:  1984-11       Impact factor: 9.319

7.  Comparing the use and discontinuation of antipsychotics in clinical practice: an observational study.

Authors:  Mark Taylor; Polash Shajahan; Stephen M Lawrie
Journal:  J Clin Psychiatry       Date:  2008-02       Impact factor: 4.384

8.  Antipsychotic polypharmacy at the University Psychiatric Hospital in Serbia.

Authors:  Nevena Divac; Miroslava Jasović-Gasić; Ranka Samardzić; Maja Lacković; Milica Prostran
Journal:  Pharmacoepidemiol Drug Saf       Date:  2007-11       Impact factor: 2.890

9.  Pharmacotherapy of first episode psychosis in Estonia: comparison with national and international treatment guidelines.

Authors:  J Lass; A Männik; J S Bell
Journal:  J Clin Pharm Ther       Date:  2008-04       Impact factor: 2.512

10.  Pattern of therapeutic intervention and role of psychiatric settings: a survey in two regions of Italy.

Authors:  G Muscettola; M Casiello; P Bolline; G Sebastiani; S Pampallona; G Tognoni
Journal:  Acta Psychiatr Scand       Date:  1987-01       Impact factor: 6.392
View more
  35 in total

1.  Correlates of Clozapine Use after a First Episode of Schizophrenia: Results From a Long-term Prospective Study.

Authors:  Alp Üçok; Ugur Çıkrıkçılı; Ceylan Ergül; Öznur Tabak; Ada Salaj; Sercan Karabulut; Christoph U Correll
Journal:  CNS Drugs       Date:  2016-10       Impact factor: 5.749

2.  Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis.

Authors:  Britta Galling; Alexandra Roldán; Katsuhiko Hagi; Liz Rietschel; Frozan Walyzada; Wei Zheng; Xiao-Lan Cao; Yu-Tao Xiang; Mathias Zink; John M Kane; Jimmi Nielsen; Stefan Leucht; Christoph U Correll
Journal:  World Psychiatry       Date:  2017-02       Impact factor: 49.548

3.  Evaluation of different approaches for confounding in nonrandomised observational data: a case-study of antipsychotics treatment.

Authors:  E Sarlon; A Millier; S Aballéa; M Toumi
Journal:  Community Ment Health J       Date:  2014-04-03

4.  Antipsychotic combinations in schizophrenia.

Authors:  C Gastaldon; D Papola; G Ostuzzi
Journal:  Epidemiol Psychiatr Sci       Date:  2017-06-05       Impact factor: 6.892

5.  A randomized double-blind controlled trial to assess the benefits of amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill schizophrenia patients (COMBINE): methods and design.

Authors:  Christian Schmidt-Kraepelin; Sandra Feyerabend; Christina Engelke; Mathias Riesbeck; Eva Meisenzahl-Lechner; Wolfgang Gaebel; Pablo-Emilio Verde; Henrike Kolbe; Christoph U Correll; Stefan Leucht; Stephan Heres; Michael Kluge; Christian Makiol; Andrea Neff; Christina Lange; Susanne Englisch; Mathias Zink; Berthold Langguth; Timm Poeppl; Dirk Reske; Euphrosyne Gouzoulis-Mayfrank; Gerhard Gründer; Alkomiet Hasan; Anke Brockhaus-Dumke; Markus Jäger; Jessica Baumgärtner; Thomas Wobrock; Joachim Cordes
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2019-09-05       Impact factor: 5.270

Review 6.  Delayed Initiation of Clozapine Continues to Be a Substantial Clinical Concern.

Authors:  Alexander Panickacheril John; Elvin Kay Fon Ko; Arun Dominic
Journal:  Can J Psychiatry       Date:  2018-04-22       Impact factor: 4.356

7.  Clozapine linked to nanocapsules minimizes tissue and oxidative damage to biomolecules lipids, proteins and DNA in brain of rats Wistar.

Authors:  Angélica Aparecida da Costa Güllich; Ritiéle Pinto Coelho; Bruna Cocco Pilar; Deise Jaqueline Ströher; Leandro Alex Sander Leal Galarça; Simone Machado Vieira; Jacqueline da Costa Escobar Piccoli; Sandra Elisa Haas; Vanusa Manfredini
Journal:  Metab Brain Dis       Date:  2014-10-09       Impact factor: 3.584

8.  Antipsychotic polypharmacy in children and adolescents at discharge from psychiatric hospitalization.

Authors:  Shannon N Saldaña; Brooks R Keeshin; Anna M Wehry; Thomas J Blom; Michael T Sorter; Melissa P DelBello; Jeffrey R Strawn
Journal:  Pharmacotherapy       Date:  2014-07-03       Impact factor: 4.705

Review 9.  Prevalence and correlates of antipsychotic polypharmacy in children and adolescents receiving antipsychotic treatment.

Authors:  Nitin Toteja; Juan A Gallego; Ema Saito; Tobias Gerhard; Almut Winterstein; Mark Olfson; Christoph U Correll
Journal:  Int J Neuropsychopharmacol       Date:  2013-05-14       Impact factor: 5.176

10.  Antipsychotic polypharmacy: a Japanese survey of prescribers' attitudes and rationales.

Authors:  Taishiro Kishimoto; Koichiro Watanabe; Hiroyuki Uchida; Masaru Mimura; John M Kane; Christoph U Correll
Journal:  Psychiatry Res       Date:  2013-04-18       Impact factor: 3.222
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.